IMCR - Immunocore Holdings plc Market Value to Book Value Ratio

IMCR (Immunocore Holdings plc) - company brandmark

Immunocore Holdings plc (IMCR) creates unique TCR solutions for the therapy of ocular melanomas, focusing on the solid tumor segment. Drug development relies on automated synthesis with physician participation during trials. New targeted therapies have only just begun their commercial journey, and their cost is 3.79. The share price visualized below on the GURU.Markets platform confirms the current fundamental status of this biopharmaceutical business.

Immunocore Corp (IMCR) Capitalization to Book Value Ratio: for the period 07/04/2022 - 10/31/2026

Analytical breakdowns for Immunocore Holdings plc

- market value and analyst target forecast:
Price Chart Immunocore Holdings plc|IMCR - Fair Value Consensus
- market capitalization statistics:
Market Value Immunocore PLC|IMCR - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Immunocore|IMCR - Accounting Capitalization|Market Capitalization to Book Value Ratio immunocore.com|IMCR - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity Immunocore Holdings plc|IMCR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Immunocore PLC|IMCR - Company Debts|Debt to Book Capitalization Ratio Immunocore PLC|IMCR - Long-Term Debt|Company Short-Term Debts Immunocore|Quick Liquidity Indicator immunocore.com
- earnings and market multiples details:
IMCR - Company Net Income
Fundamental valuation:Immunocore Holdings plc
Manufactured product of Immunocore PLC

Investing in Immunocore Holdings plc (IMCR) requires a clear distinction between the actual value of assets and market expectations. This relative market capital valuation metric compares the company's market value with its net assets, revealing the extent of business overvaluation or capital impairment. For Immunocore Holdings plc (IMCR), this metric is critical, as high R&D expenses and uncertainty regarding the expanded application of the drug Kimmtrak could lead to a significant gap between book value and market quotes.

Analysis of competing companies

ImmunityBio, Inc. (IBRX) - Market Value to Book Value Ratio|januxrx.com - Market Value to Book Value|Market Value to Book Value Ratio Arcus Biosciences|Market-to-Book Ratio Zymeworks Inc ZYME|Market Value to Book Value Ratio Tango Pharma (TNGX)|Iovance Corp - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio IMTX (Immatics N.V.)|XNCR - Market Cap to Net Assets Ratio|CMPX - Market Value to Book Value Ratio|Market-to-Book Ratio Replimune Group Inc|Lyell Immunopharma Inc (LYEL) - Market Value to Book Value Ratio|IPHA (Innate Pharma S.A) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Pyxis Oncology Inc.|Market-to-Book Ratio Compugen Limited CGEN|Market Capitalization to Book Value Ratio IOBT|Sutro Biopharma Inc. (STRO) - Market Value to Equity Ratio|MiNK - Market Cap to Net Assets Ratio|Werewolf Therapeutics Inc. (HOWL) - Market-to-Book Ratio|IMMX: Market Cap to Net Assets Ratio|Market Value to Book Value ALXO (alxoncology.com)|CUE: Market Capitalization to Book Value Ratio|PDSB - Market Capitalization to Book Value|Market Value to Book Value Ratio Sonnet BioTherapeutics Holdings, Inc.|Market Cap to Net Assets Ratio MAIA Bio (MAIA)|Market Value to Book Value Ratio Liminatus Pharma (LIMN)|Market Cap to Net Assets Ratio lavatherapeutics.com LVTX|NextCure - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Leap Therapeutics Inc LPTX|INTS - Market Value to Book Value Ratio|SNSE (Sensei Biotherapeutics) - Capitalization to Book Value Ratio|Theriva Biologics, Inc. (TOVX) - Market Value to Book Value Ratio|Market-to-Book Ratio Gritstone bio (GRTS)|Market Cap to Net Assets Ratio KA|NEXI - Market Value to Equity Ratio|Market Cap to Net Assets Ratio TSBX (Turnstone Biologics)|Market Cap to Book Value Multiple VCNX|Market Capitalization to Book Value Ratio HARP (Harpoon Therapeutics)